SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 196 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.93 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $92,576 | -45.4% | 52,600 | -2.6% | 0.00% | -50.0% |
| Q4 2022 | $169,560 | -30.0% | 54,000 | +9.3% | 0.00% | -33.3% |
| Q3 2022 | $242,060 | -25.3% | 49,400 | +37.2% | 0.00% | 0.0% |
| Q3 2021 | $324,000 | -40.7% | 36,000 | -21.1% | 0.00% | -40.0% |
| Q2 2021 | $546,000 | -8.2% | 45,600 | -4.0% | 0.01% | -16.7% |
| Q1 2021 | $595,000 | -1.2% | 47,500 | +23.1% | 0.01% | 0.0% |
| Q4 2020 | $602,000 | +125.5% | 38,600 | +36.4% | 0.01% | +100.0% |
| Q3 2020 | $267,000 | +9.9% | 28,300 | +4.4% | 0.00% | 0.0% |
| Q2 2020 | $243,000 | +135.9% | 27,100 | +68.3% | 0.00% | +200.0% |
| Q1 2020 | $103,000 | -47.2% | 16,100 | -25.1% | 0.00% | -50.0% |
| Q3 2019 | $195,000 | -13.3% | 21,500 | +2.9% | 0.00% | -33.3% |
| Q2 2019 | $225,000 | +27.8% | 20,900 | +13.6% | 0.00% | +50.0% |
| Q1 2019 | $176,000 | -64.7% | 18,400 | -57.7% | 0.00% | -71.4% |
| Q4 2018 | $499,000 | -26.4% | 43,500 | +8.8% | 0.01% | -12.5% |
| Q3 2018 | $678,000 | – | 40,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
| WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
| Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
| Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
| Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
| Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
| CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
| XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
| Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |